Home  >  News
you can get e-magazine links on WhatsApp.Click here
Marketing + Font Resize -

Neuraxpharm inks licensing pact with Bened Biomedical to introduce probiotic product, PS128 in European market

Langenfeld, Germany
Wednesday, May 29, 2019, 09:00 Hrs  [IST]

Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces it will soon launch its first probiotic in the European market following an exclusive licensing agreement with the probiotics company Bened Biomedical Co., Ltd.

Bened Biomedical, an award winning 2015 spin-out from Taiwan-based National Yang-Ming University, develops functional probiotic strains that can alter human microbiome. The agreement secures Neuraxpharm exclusive rights to market its first probiotic, PS128, in the European market.

This is Neuraxpharm's first launch of a probiotic product expanding the Company's portfolio of marketed Consumer Healthcare products. This is in line with its ambition of covering CNS therapeutics from prevention over standard therapeutics to value-added medicines. As the European Consumer Healthcare market continues to grow, this agreement opens new opportunities to promote the benefits of a broader range of probiotics to healthcare professionals and consumers.

In the last decades several studies have shown a crosstalk within the brain-gut-microbiome axis and the way gut and brain communicate. This occurs through the dynamic population of microorganisms (the gut microbiome) colonising the gastrointestinal tract, producing metabolites and interacting with the enteric nervous system and with the central nervous system.

The new Consumer Healthcare product will be manufactured in Europe and will first be launched in the Italian market, followed by other countries building on Neuraxpharm's European presence.

Dr. Jörg-Thomas Dierks, CEO of Neuraxpharm said, "We are delighted to launch our first probiotic into the European market. Our mission is to raise the standards of mental health care, and we continue to be committed to offering diversified and affordable products. We are deeply aware of the substantial unmet need in this area, and our goal is to make a proven and positive difference in the lives of millions of people struggling with mental health."

Frankie Cheng, CEO of Bened Biomedical commented, "I am enthusiastic to bring PS128 to the European market. We look forward to implementing this agreement with Neuraxpharm as it offers a unique approach to the support of people battling CNS disorders, which we believe will be welcomed by doctors and patients alike."


* Name :     
* Email :    
  Website :  
Copyright © 2016 Saffron Media Pvt. Ltd |